Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Capstone Holding Corp. Board/Management Information 2016

Mar 18, 2016

35323_rns_2016-03-18_9a75e72d-342a-44d5-b856-644e0cb96822.zip

Board/Management Information

Open in viewer

Opens in your device viewer

8-K 1 f8k_031816.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____

FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report: March 15, 2016 (Date of earliest event reported)

CAPSTONE THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
Delaware 000-21214 86-0585310
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

| 1275 West Washington Street, Suite 104,
Tempe, Arizona | 85281 |
| --- | --- |
| (Address of principal executive offices) | (Zip Code) |

Registrant’s telephone number, including area code: (602) 286-5520

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Field: Page; Sequence: 1

Field: /Page

Section 5 - Corporate Governance and Management

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 15, 2016, Eric W. Fangmann notified the Company that, effective immediately, he was resigning from the Company’s Board of Directors and the Company’s Audit Committee. Eric W. Fangmann has served as a director of the Company since being elected by Stockholders on June 12, 2014. Eric W. Fangmann is the Chief Financial Officer of various business entities associated with Lloyd I. Miller, III. Lloyd I. Miller, III currently owns 7,926,389 shares, or approximately 19.4%, of the Company’s outstanding common stock. Lloyd I. Miller, III, is not a related party or otherwise affiliated with the Company, its directors or officers, except that Lloyd I. Miller, III, recommended Eric W. Fangmann to be a Company Board of Director member.

We are not aware of any disagreement with Mr. Fangmann as defined in 17 CFR 240.3b-7. Mr. Fangmann has informed the Board that his decision to resign is due to personal and business commitments.

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 18, 2016
/s/ John M. Holliman, III
John M. Holliman, III
Executive Chairman and CEO